Addendum
Elotuzumab (multiple myeloma) - Addendum to Commission A19-80
Report documents
-
Addendum
Elotuzumab (multiple myeloma) - Addendum to Commission A19-80
Dossier assessment
Indication:
Adult patients with relapsed and refractory multiple myeloma after at least 2 prior therapies (including lenalidomide and a proteasome inhibitor) and disease progression on the last therapy
Result of dossier assessment:
Conclusion of dossier assessment A19-80 unchanged: indication of minor added benefit
Additional information
Federal Joint Committee (G-BA)
2020-04-02 A G-BA decision was published.
Project details
- Project no.
- A20-12
- Commission
- Commission awarded on 10.03.2020 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed